Real-world usage profile of flecainide in a cardiology outpatient setting: a retrospective observational study
Real-world data on flecainide use in older, multimorbid patients remain limited. This retrospective observational study analyzed the electronic medical records of 31 adults prescribed flecainide at a cardiology outpatient clinic (February–May 2025). The cohort was predominantly older (mean age 71.9 ± 9.5 years) and female (71.0%), and most patients had arterial hypertension (83.9%). Therapy modification was required in 32.3% of patients; higher diastolic blood pressure was associated with modification (OR 1.15 per 1 mmHg, 95% CI: 1.01–1.30), but this association was not observed in a complete-case sensitivity analysis. Adverse drug reactions were documented in 12.9% of patients, none of which were attributable to flecainide. Clinical improvement was documented in 14 of 21 patients with follow-up data (66.7%), and therapy modification was associated with lower odds of improvement (adjusted OR 0.046, 95% CI: 0.003–0.618). These exploratory findings suggest acceptable short-term tolerability of flecainide in carefully selected older patients.
Authors
- Violeta Getova-Kolarova (ORCID: https://orcid.org/0000-0002-7103-3892)
- Evgeni Grigorov (ORCID: https://orcid.org/0000-0002-8290-5182)
- Илко Гетов
- Emilia Naseva
Institutions
- Medical University of Varna (BG)
- Medical University of Sofia (BG)
Publication Details
- Journal
- Pharmacia
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3897/pharmacia.73.e216973
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- NextGenerationEU